EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Rubicon Organics's enterprise value is $28.85 Mil.
Rubicon Organics's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was $2.26 Mil. Therefore, Rubicon Organics's EV-to-EBITDA for today is 12.76.
The historical rank and industry rank for Rubicon Organics's EV-to-EBITDA or its related term are showing as below:
ROMJF'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -24.9 Med: -4.12 Max: 313.48
Current: 12.76
During the past 10 years, the highest EV-to-EBITDA of Rubicon Organics was 313.48. The lowest was -24.90. And the median was -4.12.
ROMJF's EV-to-EBITDA is ranked worse than 50.54% of 740
companies
in the Drug Manufacturers industry
Industry Median: 12.955
vs ROMJF: 12.76
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Rubicon Organics's PE Ratio (TTM) for today is calculated as:
Rubicon Organics's share price for today is $0.32094.
Rubicon Organics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.015.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Rubicon Organics's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Rubicon Organics's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Rubicon Organics EV-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Rubicon Organics's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Rubicon Organics's EV-to-EBITDA falls into.
Rubicon Organics's current Enterprise Value is $28.85 Mil.
Rubicon Organics's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $2.26 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Rubicon Organics (ROMJF) has a EV-to-EBITDA of 12.76 as of Jul. 08, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Rubicon Organics. According to the industry distribution chart, Rubicon Organics ranks #374 out of 740 companies in the Drug Manufacturers industry, placing it in the top 50.5%.
Is Rubicon Organics' EV-to-EBITDA too high?
Rubicon Organics' current EV-to-EBITDA is 12.76. The Drug Manufacturers industry median EV-to-EBITDA is 12.96. Rubicon Organics' value of 12.76 is 1.5% below this industry median. Based on the distribution chart, Rubicon Organics ranks #374 out of 740 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Rubicon Organics has a GF Score™ of 50/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Rubicon Organics' EV-to-EBITDA compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Rubicon Organics ranks #374 out of 740 companies for EV-to-EBITDA. This places Rubicon Organics in the lower half of its industry. The industry median EV-to-EBITDA is 12.96. Rubicon Organics' value of 12.76 is 1.5% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Drug Manufacturers company?
The median EV-to-EBITDA among Drug Manufacturers companies is 12.96, based on 740 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Rubicon Organics's current EV-to-EBITDA of 12.76 is 1.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Rubicon Organics. For the Drug Manufacturers industry, the median EV-to-EBITDA is 12.96 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Rubicon Organics's current EV-to-EBITDA is 12.76. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Rubicon Organics stock overvalued right now?
Based on GuruFocus' analysis, Rubicon Organics (ROMJF) is currently considered Modestly Undervalued. The stock's GF Value™ is $0.37, compared to a current price of $0.32 — trading 13.3% below its estimated fair value. The current EV-to-EBITDA is 12.76 and 1.5% below the Drug Manufacturers industry median of 12.96. Rubicon Organics' overall GF Score™ is 50/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Rubicon Organics (ROMJF), the current EV-to-EBITDA is 12.76 as of Jul. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Rubicon Organics (ROMJF) Overvalued in 2026?
Based on GuruFocus' analysis, Rubicon Organics stock appears to be undervalued.
The current stock price of $0.32 is trading 13.3% below its estimated GF Value™ of $0.37.
GuruFocus considers Rubicon Organics to be Modestly Undervalued.
Key valuation signals for ROMJF:
EV-to-EBITDA: 12.76
GF Value™: $0.37 vs. price of $0.32 (13.3% below fair value)
Industry Position: 1.5% below the Drug Manufacturers median (#374 of 740)
No single metric tells the full story. See the ROMJF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Rubicon Organics Inc is engaged in the production and sale of cannabis in Canada. The company produces and processes organic cannabis at its wholly owned, federally licensed 125,000 square foot facility in Delta, British Columbia which it sells under its wholly owned brands and certain wholesale channels. Its brands include Simply Bare, 1964 Supply Co, Wildflower, and Homestead Cannabis Supply. It operates in a single reportable segment, being the production and sale of cannabis in Canada.
50GF Score
Get the complete analysis for ROMJF
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROMJF has been successfully added to your 
